AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27087946 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia
Number of subjects: 330
Study 27087946 — intervention group
Group type: COMPARATOR
Intervention: GERD
Number of subjects: 330
Study 27088163 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based classification of CLRD cases and exacerbations
Number of subjects: 216
Study 27088859 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg/d for 8 weeks
Number of subjects: 31
Study 27089287 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal sensory stimulation
Number of subjects: 0
Study 27089287 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation
Number of subjects: 0
Study 27089287 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex stimuli
Number of subjects: 0
Study 27089287 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve stimulation
Number of subjects: 0
Study 27090116 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA with injection reminder function
Number of subjects: 669
Study 27090116 — intervention group
Group type: COMPARATOR
Intervention: PDA without injection reminder function
Number of subjects: 669
Study 27090116 — intervention group
Group type: COMPARATOR
Intervention: Paper patient diary
Number of subjects: 669
Study 27090116 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA (male patients)
Number of subjects: 669
Study 27090176 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic assays (pyrosequencing of seven Mycobacterium tuberculosis gene regions)
Number of subjects: 1128
Study 27090231 — intervention group
Group type: EXPERIMENTAL
Intervention: VARYITY (4 different active videogames during 4, 15-min bouts)
Number of subjects: 23
Study 27090231 — intervention group
Group type: COMPARATOR
Intervention: NON-VARIETY (only 1 active videogame during 4, 15-min bouts)
Number of subjects: 23
Study 27090231 — intervention group
Group type: EXPERIMENTAL
Intervention: VARYITY
Number of subjects: 23
Study 27090231 — intervention group
Group type: COMPARATOR
Intervention: NON-VARIETY
Number of subjects: 23
Study 27090577 — intervention group
Group type: EXPERIMENTAL
Intervention: PCST + BWM
Number of subjects: 169
Study 27090577 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 169
Study 27090917 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin injection at the upper inner thigh
Number of subjects: 75
Study 27090917 — intervention group
Group type: COMPARATOR
Intervention: Insulin injection at the outer thigh
Number of subjects: 75
Study 27091189 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment in Korean MDD patients
Number of subjects: 109
Study 27091189 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatment in STAR*D level 1 (n=1677)
Number of subjects: 109
Study 27091421 — intervention group
Group type: EXPERIMENTAL
Intervention: LFA102 at 60 mg/kg intravenously once every 4 weeks
Number of subjects: 73
Study 27091459 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 10
Study 27091674 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTube playlist plus standard education
Number of subjects: 65
Study 27091674 — intervention group
Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 65
Study 27091719 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-based fMRI in patients with schizophrenia
Number of subjects: 30
Study 27091719 — intervention group
Group type: COMPARATOR
Intervention: Task-based fMRI in healthy controls
Number of subjects: 30
Study 27091719 — intervention group
Group type: EXPERIMENTAL
Intervention: Task 1 and Task 2 (emotional processing)
Number of subjects: 30
Study 27091719 — intervention group
Group type: EXPERIMENTAL
Intervention: Task 3 (mental rotation task)
Number of subjects: 30
Study 27091847 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical or catheter-based treatment of VSD (5.2% of cases, 181 children)
Number of subjects: 3495
Study 27091847 — intervention group
Group type: COMPARATOR
Intervention: Isolated VSDs (no treatment specified)
Number of subjects: 3495
Study 27092197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (dabigatran), taken twice daily (bid) according to label recommendation
Number of subjects: 6148
Study 27092334 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided biliary drainage (EUS-BD)
Number of subjects: 96
Study 27092830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks
Number of subjects: 655
Study 27092830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 655
Study 27093159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin for 18 months
Number of subjects: 89
Study 27093291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ring delivering 150 mg DL-lactic acid for 7 days
Number of subjects: 6
Study 27093291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ring delivering 150 mg DL-lactic acid
Number of subjects: 6
Study 27093365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (anti-PD-1) at a dose of 2 mg/kg every 3 weeks
Number of subjects: 26
Study 27093365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (anti-PD-1)
Number of subjects: 26
Study 27094359 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD devices from Biotronik
Number of subjects: 953
Study 27094359 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D devices
Number of subjects: 953
Study 27094359 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Scientific devices
Number of subjects: 953
Study 27094359 — intervention group
Group type: COMPARATOR
Intervention: ICD devices
Number of subjects: 953
Study 27094359 — intervention group
Group type: EXPERIMENTAL
Intervention: System failure
Number of subjects: 953
Study 27094359 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of ventricular pacing
Number of subjects: 953
Study 27094394 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Inspiratory Pressure (PImax) assessment using a U-type water manometer
Number of subjects: 0
Study 27094394 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-grip force assessment using a hydraulic hand dynamometer
Number of subjects: 0
Study 27094394 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilinear regression model including hand-grip force, sex, and body mass index
Number of subjects: 0
Study 27094444 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative RA patients
Number of subjects: 234
Study 27094444 — intervention group
Group type: COMPARATOR
Intervention: Seropositive RA patients
Number of subjects: 234
Study 27094489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aspirin
Number of subjects: 0
Study 27094489 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 0
Study 27094489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral aspirin and folic acid
Number of subjects: 0
Study 27094489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 0
Study 27095043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine challenge dose (10μg HBs antigen)
Number of subjects: 303
Study 27095237 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 600 mg
Number of subjects: 671
Study 27095237 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 1200 mg
Number of subjects: 671
Study 27095237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 27095249 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to Accept (WTA) for informal care
Number of subjects: 93
Study 27095249 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to Pay (WTP) for informal care
Number of subjects: 93
Study 27095249 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to Pay (WTP) for informal care in urban areas
Number of subjects: 93
Study 27095249 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to Pay (WTP) for informal care in rural areas
Number of subjects: 93
Study 27095249 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to Pay (WTP) for informal care by wealth quintile
Number of subjects: 93
Study 27095604 — intervention group
Group type: EXPERIMENTAL
Intervention: Online motivational interviewing (MI) intervention, consisting of six individual 30-minute sessions over 18 months, delivered by doctoral-level psychologists.
Number of subjects: 0
Study 27095604 — intervention group
Group type: COMPARATOR
Intervention: Group-based online behavioral weight control program alone.
Number of subjects: 0
Study 27095636 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived fibroblasts
Number of subjects: 0
Study 27095636 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMA1 knockdown in human neuronal cells
Number of subjects: 0
Study 27096100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic delivery of autologous dendritic cells (DCs)
Number of subjects: 9
Study 27096100 — intervention group
Group type: COMPARATOR
Intervention: Intranodal and intradermal backup options
Number of subjects: 9
Study 27096100 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort survival
Number of subjects: 9
Study 27096100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranodal route of DC vaccines
Number of subjects: 9
Study 27096106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone
Number of subjects: 36
Study 27096572 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine screening for creatine transporter deficiency (CTD)
Number of subjects: 55
Study 27096572 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine creatine and creatinine levels measurement
Number of subjects: 55
Study 27096755 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot towel (n = 22)
Number of subjects: 90
Study 27096755 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeGiene (n = 22)
Number of subjects: 90
Study 27096755 — intervention group
Group type: EXPERIMENTAL
Intervention: Blephasteam (n = 22)
Number of subjects: 90
Study 27096755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiflow (n = 24)
Number of subjects: 90
Study 27096755 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (n = 90)
Number of subjects: 90
Study 27096755 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography features
Number of subjects: 90
Study 27097163 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial treatment for 8 weeks
Number of subjects: 0
Study 27097163 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in the SLC11A1 gene
Number of subjects: 0
Study 27098021 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAVI DNA-C2 (4 mg) and SAAVI MVA-C (1.45 × 10(9) PFU)
Number of subjects: 48
Study 27098021 — intervention group
Group type: EXPERIMENTAL
Intervention: gp140/MF59 (100 μg)
Number of subjects: 48
Study 27098021 — intervention group
Group type: EXPERIMENTAL
Intervention: gp140/MF59
Number of subjects: 48
Study 27098021 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAVI DNA-MVA regimen
Number of subjects: 48
Study 27098021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 27098105 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 13833
Study 27098522 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions to increase CRC screening uptake
Number of subjects: 0
Study 27098522 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy knowledge score
Number of subjects: 0
Study 27098749 — intervention group
Group type: EXPERIMENTAL
Intervention: BMX-001 (manganese porphyrin) administered subcutaneously
Number of subjects: 0
Study 27098749 — intervention group
Group type: EXPERIMENTAL
Intervention: BMX-001 (manganese porphyrin)
Number of subjects: 0
Study 27099175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nav1.7 sodium channel blocker (new potent and selective compound)
Number of subjects: 5
Study 27099175 — intervention group
Group type: EXPERIMENTAL
Intervention: iPSC-derived sensory neurons emulating clinical phenotype
Number of subjects: 5
Study 27099175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nav1.7 blockers (including clinical test agent)
Number of subjects: 5
Study 27099244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Yorkhill Malnutrition Score (PYMS)
Number of subjects: 2567
Study 27099244 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP)
Number of subjects: 2567
Study 27099244 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Tool for Risk of Impaired Nutritional Status and Growth (STRONGKIDS)
Number of subjects: 2567
Study 27099244 — intervention group
Group type: EXPERIMENTAL
Intervention: PYMS
Number of subjects: 2567
Study 27099244 — intervention group
Group type: EXPERIMENTAL
Intervention: STAMP
Number of subjects: 2567
Study 27099244 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONGKIDS
Number of subjects: 2567
Study 27099252 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I (apo A-I)
Number of subjects: 15602
Study 27099252 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 15602
Study 27099252 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 15602
Study 27099252 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B-100 (apo B-100)
Number of subjects: 15602
Study 27099252 — intervention group
Group type: COMPARATOR
Intervention: LDL cholesterol
Number of subjects: 15602
Study 27099766 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 557 (1.8-210 mg subcutaneous or 18 mg intravenous single dose; 6-210 mg subcutaneous every other week for multiple doses)
Number of subjects: 112
Study 27099766 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 557
Number of subjects: 112
Study 27099955 — intervention group
Group type: EXPERIMENTAL
Intervention: CFH risk alleles (0 to 2)
Number of subjects: 835
Study 27099955 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS2 risk alleles (0 to 2)
Number of subjects: 835
Study 27099955 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 risk alleles (0 to 2)
Number of subjects: 835
Study 27100299 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (1 or 2 years)
Number of subjects: 5099
Study 27100299 — intervention group
Group type: COMPARATOR
Intervention: No trastuzumab
Number of subjects: 5099
Study 27101216 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular approach (SCL)
Number of subjects: 101
Study 27101216 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular approach (ICL)
Number of subjects: 101
Study 27101216 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary approach (AX)
Number of subjects: 101
Study 27101216 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 101
Study 27101285 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-angiogenic therapy
Number of subjects: 14
Study 27101536 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential celiac disease
Number of subjects: 125
Study 27101536 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial or subtotal villous atrophy (P/SVA)
Number of subjects: 125
Study 27101536 — intervention group
Group type: EXPERIMENTAL
Intervention: Total villous atrophy (TVA)
Number of subjects: 125
Study 27101536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 27101536 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with P/SVA
Number of subjects: 125
Study 27101538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin measurement using ELISA assay
Number of subjects: 87
Study 27101538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiological diagnosis by routine light microscopy, quantitative egg counts, and Giardia antigen test
Number of subjects: 87
Study 27102120 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS + SoC
Number of subjects: 0
Study 27102120 — intervention group
Group type: COMPARATOR
Intervention: SoC alone
Number of subjects: 0
Study 27102120 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 0
Study 27102201 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic aortic surgery
Number of subjects: 228
Study 27102201 — intervention group
Group type: COMPARATOR
Intervention: Conventional open aortic surgery
Number of subjects: 228
Study 27102499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 222
Study 27102499 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 222
Study 27102499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (crossover patients)
Number of subjects: 222
Study 27102949 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Number of subjects: 18
Study 27103198 — intervention group
Group type: COMPARATOR
Intervention: Paper-based workflow protocol (PaperG: 37 patients)
Number of subjects: 79
Study 27103198 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medication management system (CompG: 42 patients)
Number of subjects: 79
Study 27103349 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2126458 (a novel, potent PI3K/mTOR inhibitor)
Number of subjects: 0
Study 27103349 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2126458
Number of subjects: 0
Study 27103591 — intervention group
Group type: EXPERIMENTAL
Intervention: 2008 tobacco control policies (extension of smoke-free law to hospitality industry, tax increase, mass media campaign)
Number of subjects: 2069695
Study 27103591 — intervention group
Group type: COMPARATOR
Intervention: 2004 tobacco control policies (smoke-free legislation in workplaces, tax increase, mass media campaign)
Number of subjects: 2069695
Study 27105343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemrix™ (D-Pan)
Number of subjects: 56
Study 27105343 — intervention group
Group type: EXPERIMENTAL
Intervention: Arepanrix™ (Q-Pan)
Number of subjects: 56
Study 27105343 — intervention group
Group type: COMPARATOR
Intervention: Both D-Pan and Q-Pan
Number of subjects: 56
Study 27105716 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative Nicotine Delivery Systems (ANDS) use
Number of subjects: 100
Study 27105716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment
Number of subjects: 100
Study 27105716 — intervention group
Group type: EXPERIMENTAL
Intervention: Geospatial assessment
Number of subjects: 100
Study 27105716 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews
Number of subjects: 100
Study 27105716 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva cotinine and exhaled carbon monoxide (CO) biomarkers
Number of subjects: 100
Study 27105716 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-related and ANDS-related rules and norms
Number of subjects: 100
Study 27105716 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective effects of ANDS use
Number of subjects: 100
Study 27106070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA (BoNT-ONA) injections
Number of subjects: 52
Study 27106364 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier cotwins
Number of subjects: 16
Study 27106364 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 16
Study 27106966 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-BANG score
Number of subjects: 630
Study 27106966 — intervention group
Group type: EXPERIMENTAL
Intervention: New score based on two retained STOP-BANG questions (treatment for hypertension and neck circumference >40 cm)
Number of subjects: 630
Study 27107887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 158
Study 27107887 — intervention group
Group type: COMPARATOR
Intervention: Shunt
Number of subjects: 158
Study 27107887 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV
Number of subjects: 158
Study 27108080 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hypofractionated three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, combined with platinum doublet chemotherapy
Number of subjects: 12
Study 27108156 — intervention group
Group type: COMPARATOR
Intervention: Peak longitudinal strain (PLS) in necrotic segments
Number of subjects: 98
Study 27108156 — intervention group
Group type: COMPARATOR
Intervention: Post-systolic deformation index (PSI) in necrotic segments
Number of subjects: 98
Study 27108156 — intervention group
Group type: COMPARATOR
Intervention: Pre-STretch index (PST) in necrotic segments
Number of subjects: 98
Study 27108156 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI with a cutoff value of 8%
Number of subjects: 98
Study 27108156 — intervention group
Group type: EXPERIMENTAL
Intervention: PLS with a cutoff value of -13%
Number of subjects: 98
Study 27108156 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of PSI and PST to PLS
Number of subjects: 98
Study 27108845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanczos2 (high quality Nyquist bandlimited downsampling filter)
Number of subjects: 3
Study 27108845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanczos2
Number of subjects: 3
Study 27108845 — intervention group
Group type: COMPARATOR
Intervention: MVP (minimal vision processing)
Number of subjects: 3
Study 27108845 — intervention group
Group type: COMPARATOR
Intervention: System off
Number of subjects: 3
Study 27108845 — intervention group
Group type: COMPARATOR
Intervention: WV (wide view regional averaging filtering)
Number of subjects: 3
Study 27108845 — intervention group
Group type: COMPARATOR
Intervention: Scrambled
Number of subjects: 3
Study 27109457 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic unroofing
Number of subjects: 14
Study 27109549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 15 mg/m2 orally once daily for 4 weeks every 6 weeks
Number of subjects: 30
Study 27109549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 30
Study 27110364 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) during cycling
Number of subjects: 25
Study 27110364 — intervention group
Group type: COMPARATOR
Intervention: Placebo Functional Electrical Stimulation (FES) during cycling
Number of subjects: 25
Study 27110376 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Centered Empowerment Model (FCEM)
Number of subjects: 70